⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL221597 | 0.87 | SIGMAR1 (0.54) | — | |
| SCHEMBL7019855 | 0.85 | SIGMAR1 (0.57) | — | |
| SCHEMBL737232 | 0.82 | — | — | |
| SCHEMBL28172212 | 0.70 | SIGMAR1 (0.43) | — | |
| SCHEMBL224421 | 0.70 | SIGMAR1 (0.54) | — | |
| SCHEMBL27008 | 0.69 | — | — | |
| SCHEMBL7449194 | 0.68 | SIGMAR1 (0.57) | — | |
| SCHEMBL449670 | 0.68 | SIGMAR1 (0.42) | — | |
| SCHEMBL9209559 | 0.68 | SIGMAR1 (0.42) | — | |
| SCHEMBL8348679 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025891-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CELGENE CORPORATION | 2024-01-25 | — | — | US | claimed |
| EP-4232449-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | Celgene Corporation (US) | 2023-08-30 | — | — | EP | claimed |
| US-20230146944-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | SIGNAL PHARMACEUTICALS, LLC | 2023-05-11 | — | — | US | claimed |
| WO-2022087326-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CELGENE CORPORATION (US) | 2022-04-28 | — | — | WO | claimed |
| EP-3959207-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | Celgene Corporation (US) | 2022-03-02 | — | — | EP | claimed |
| EP-3340796-B1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION INC (US) | 2021-04-21 | — | — | EP | claimed |
| US-20200339559-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CELGENE CORPORATION | 2020-10-29 | — | — | US | claimed |
| WO-2020219871-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CELGENE CORPORATION (US) | 2020-10-29 | — | — | WO | claimed |
| US-20190167821-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. | 2019-06-06 | — | — | US | claimed |
| US-10137211-B2 | Probes for imaging Huntingtin protein | CHDI FOUNDATION, INC. (US) | 2018-11-27 | — | — | US | claimed |
| US-20170056535-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. | 2017-03-02 | — | — | US | claimed |
| EP-1197485-B1 | Cyclobuten-dione derivatives for use in the treatment of artherosclerosis | SERVIER LAB (FR) | 2004-08-11 | — | — | EP | claimed |
| US-6696469-B2 | FOR TREATMENT OF DISEASES OR PATHOLOGICAL CONDITIONS IN WHICH ENDOTHELIAL DYSFUNCTION IS KNOWN; ATHEROSCLEROSIS, DYSLIPIDAEMIA, DIABETES | LES LABORATOIRES SERVIER (FR) | 2004-02-24 | — | — | US | claimed |
| US-20020065419-A1 | Cyclobutenedione compounds | LES LABORATOIRES SERVIER (FR) | 2002-05-30 | — | — | US | claimed |
| US-20240173419-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-05-30 | — | — | US | disclosed |
| WO-2024092011-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| WO-2024064080-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-03-28 | — | — | WO | disclosed |
| US-5278177-A | Enzyme inhibitory | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-01-11 | — | — | US | disclosed |
| US-5179115-A | Antiinflammatory agents, antiallergens | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-01-12 | — | — | US | disclosed |
| EP-0462831-A2 | Bicyclic pyran derivatives and their use as inhibitors of 5-lipoxygenase | ZENECA LIMITED (GB) | 1991-12-27 | — | — | EP | disclosed |